Early use of anti‐TNF treatment in peripheral spondyloarthritis (pSpA) can achieve sustained drug-free clinical remission in more than 50% of patients, a European study has shown. In a trial that backs the “window of opportunity” hypothesis for treatment of the very early stages of pSpA, patients whose treatment with golimumab was started within 12 weeks ...
‘Window of opportunity’: TNFi induce high rates of remission in early SpA
By Michael Woodhead
31 May 2018